Neutralization of macrophage migration inhibitory factor-novel approach for the treatment of immunoinflammatory disorders

International Immunopharmacology

Volumn 6, Issue 10, 2006, Pages 1527-1534

  Cvetkovic, Ivana ^a   Stosic Grujicic, Stanislava ^b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b NONE

Author keywords

Autoimmune disease; Immunotherapy; Inflammation; Macrophage migration inhibitory factor; MIF inhibitors

Indexed keywords

3 (4 HYDROXYPHENYL) 4,5 DIHYDRO 5 ISOXAZOLE ACETIC ACID METHYL ESTER; BOLDINE; CAFFEIC ACID; CHALCONE; COR 100140; CURCUMIN; DEXAMETHASONE; ENZYME INHIBITOR; FOLIC ACID; GENTISIC ACID; MACROPHAGE MIGRATION INHIBITION FACTOR; NEUTRALIZING ANTIBODY; PARACETAMOL; PARACETAMOL DERIVATIVE; PARTHENOLIDE; PHENYL GROUP; PHLORETIN; PLANT EXTRACT; RESVERATROL; SCOPOLETIN; STILBENE; TROPOLONE; UMBELLIFERONE; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNE DISEASE; DRUG COST; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVITY; HALF LIFE TIME; HUMAN; INFLAMMATION; MACROPHAGE MIGRATION INHIBITION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; MACROPHAGE MIGRATION-INHIBITORY FACTORS; PLANT PREPARATIONS;

EID: 33747083848     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2006.06.009     Document Type: Review

References (88)

1. Bloom B.R., and Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153 (1966) 80-82
2. David J.R. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A 56 (1966) 72-77
3. Bernhagen J., Bacher M., Calandra T., Metz C.N., Doty S.B., Donnelly T., et al. An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. J Exp Med 183 (1996) 277-282
4. Gregory J.L., Leech M.T., David J.R., Yang Y.H., Dacumos A., and Hickey M.J. Reduced leukocyte-endothelial cell interactions in the inflamed microcirculation of macrophage migration inhibitory factor-deficient mice. Arthritis Rheum 50 (2004) 3023-3034
5. Weiser W.Y., Temple P.A., Witek-Giannotti J.S., Remold H.G., Clark S.C., and David J.R. Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. Proc Natl Acad Sci U S A 86 (1989) 7522-7526
6. Bernhagen J., Mitchell R.A., Calandra T., Voelter W., Cerami A., and Bucala R. Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry 33 (1994) 14144-14155
7. Bernhagen J., Calandra T., and Bucala R. Regulation of the immune response by macrophage migration inhibitory factor: biological and structural features. J Mol Med 76 (1998) 151-161
8. Denkinger C.M., Metz C., Fingerle-Rowson G., Denkinger M.D., and Forsthuber T. Macrophage migration inhibitory factor and its role in autoimmune diseases. Arch Immunol Ther Exp (Warsz) 52 (2004) 389-400
9. Calandra T., and Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3 (2003) 791-800
10. Bernhagen J., Calandra T., Mitchell R.A., Martin S.B., Tracey K., Voelter W., et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365 (1993) 756-759
11. Rosengren E., Bucala R., Aman P., Jacobsson L., Odh G., Metz C.N., et al. The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol Med 2 (1996) 143-149
12. Calandra T., Bernhagen J., Metz C.N., Spiegel L.A., Bacher M., Donnelly T., et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377 (1995) 68-71
13. Cherepkova O.A., Lyutova E.M., Eronina T.B., and Gurvits B.Y. Chaperone-like activity of macrophage migration inhibitory factor. Int J Biochem Cell Biol 38 (2006) 43-55
14. Bacher M., Metz C.N., Calandra T., Mayer K., Chesney J., Lohoff M., et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci U S A 93 (1996) 7849-7854
15. Lehmann L.E., Weber S.U., Fuchs D., Klaschik S., Schewe J.C., Book M., et al. Intracellular detection of macrophage migration inhibitory factor in peripheral blood leukocytes. Free Radic Biol Med 38 (2005) 1170-1179
16. Calandra T., Bernhagen J., Mitchell R.A., and Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 179 (1994) 1895-1902
17. Morelli A.E., Zahorchak A.F., Larregina A.T., Colvin B.L., Logar A.J., Takayama T., et al. Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. Blood 98 (2001) 1512-1523
18. Rossi A.G., Haslett C., Hirani N., Greening A.P., Rahman I., Metz C.N., et al. Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF). Potential role in asthma. J Clin Invest 101 (1998) 2869-2874
19. Makita H., Nishimura M., Miyamoto K., Nakano T., Tanino Y., Hirokawa J., et al. Effect of anti-macrophage migration inhibitory factor antibody on lipopolysaccharide-induced pulmonary neutrophil accumulation. Am J Respir Crit Care Med 158 (1998) 573-579
20. Wiener Z., Falus A., and Toth S. IL-9 increases the expression of several cytokines in activated mast cells, while the IL-9-induced IL-9 production is inhibited in mast cells of histamine-free transgenic mice. Cytokine 26 (2004) 122-130
21. Waeber G., Calandra T., Roduit R., Haefliger J.-A., Bonny C., Thompson N., et al. Insulin secretion is regulated by the glucose-dependent production of islet beta cell macrophage migration inhibitory factor. Proc Natl Acad Sci U S A 94 (1997) 4782-4787
22. Matsui Y., Okamoto H., Jia N., Akino M., Uede T., Kitabatake A., et al. Blockade of macrophage migration inhibitory factor ameliorates experimental autoimmune myocarditis. J Mol Cell Cardiol 37 (2004) 557-566
23. Bacher M., Meinhardt A., Lan H.Y., Mu W., Metz C.N., Chesney J.A., et al. Migration inhibitory factor expression in experimentally induced endotoxemia. Am J Pathol 150 (1997) 235-246
24. Nishibori M., Nakaya N., Tahara A., Kawabata M., Mori S., and Saeki K. Presence of macrophage migration inhibitory factor (MIF) in ependyma, astrocytes and neurons in the bovine brain. Neurosci Lett 213 (1996) 193-196
25. Lan H.Y., Mu W., Yang N., Meinhardt A., Nikolic-Paterson D.J., Ng Y.Y., et al. De Novo renal expression of macrophage migration inhibitory factor during the development of rat crescentic glomerulonephritis. Am J Pathol 149 (1996) 1119-1127
26. Leng L., Metz C.N., Fang Y., Xu J., Donnelly S., Baugh J., et al. MIF signal transduction initiated by binding to CD74. J Exp Med 197 (2003) 1467-1476
27. Kleemann R., Hausser A., Geiger G., Mischke R., Burger-Kentischer A., Flieger O., et al. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 408 (2000) 211-216
28. Mitchell R.A., Metz C.N., Peng T., and Bucala R. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem 274 (1999) 18100-18106
29. Lue H., Kapurniotu A., Fingerle-Rowson G., Roger T., Leng L., Thiele M., et al. Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal 18 (2006) 688-730
30. Hudson J.D., Shoaibi M.A., Maestro R., Carnero A., Hannon G.J., and Beach D.H. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 190 (1999) 1375-1382
31. Bernhagen J., Calandra T., Cerami A., and Bucala R. Macrophage migration inhibitory factor is a neuroendocrine mediator of endotoxaemia. Trends Microbiol 2 (1994) 198-201
32. Bernhagen J., Calandra T., and Bucala R. The emerging role of MIF in septic shock and infection. Biotherapy 8 (1994) 123-127
33. Onodera S., Kaneda K., Mizue Y., Koyama Y., Fujinaga M., and Nishihira J. Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis. J Biol Chem 275 (2000) 444-450
34. Denkinger C.M., Denkinger M., Kort J.J., Metz C., and Forsthuber T.G. In vivo blockade of macrophage migration inhibitory factor ameliorates acute experimental autoimmune encephalomyelitis by impairing the homing of encephalitogenic T cells to the central nervous system. J Immunol 170 (2003) 1274-1282
35. Roger T., David J., Glauser M.P., and Calandra T. MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 414 (2001) 920-924
36. Takase H., Sugita S., Rhee D.J., Imai Y., Taguchi C., Sugamoto Y., et al. The presence of macrophage migration inhibitory factor in human trabecular meshwork and its upregulatory effects on the T helper 1 cytokine. Invest Ophthalmol Vis Sci 43 (2002) 2691-2696
37. Abe R., Peng T., Sailors J., Bucala R., and Metz C.N. Regulation of the CTL response by macrophage migration inhibitory factor. J Immunol 166 (2001) 747-753
38. Daun J.M., and Cannon J.G. Macrophage migration inhibitory factor antagonizes hydrocortisone-induced increases in cytosolic IkappaBalpha. Am J Physiol Regul Integr Comp Physiol 279 (2000) R1043-R1049
39. Roger T., Chanson A.L., Knaup-Reymond M., and Calandra T. Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. Eur J Immunol 35 (2005) 3405-3413
40. de Jong Y.P., Abadia-Molina A.C., Satoskar A.R., Clarke K., Rietdijk S.T., Faubion W.A., et al. Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol 2 (2001) 1061-1066
41. Bozza M., Satoskar A.R., Lin G., Lu B., Humbles A.A., Gerard C., et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 189 (1999) 341-346
42. Shimizu T., Abe R., Nishihira J., Shibaki A., Watanabe H., Nakayama T., et al. Impaired contact hypersensitivity in macrophage migration inhibitory factor-deficient mice. Eur J Immunol 33 (2003) 1478-1487
43. Powell N.D., Papenfuss T.L., McClain M.A., Gienapp I.E., Shawler T.M., Satoskar A.R., et al. Macrophage migration inhibitory factor is necessary for progression of experimental autoimmune encephalomyelitis. J Immunol 175 (2005) 5611-5614
44. Nakamaru Y., Oridate N., Nishihira J., Takagi D., Furuta Y., and Fukuda S. Macrophage migration inhibitory factor (MIF) contributes to the development of allergic rhinitis. Cytokine 31 (2005) 103-108
45. Mizue Y., Ghani S., Leng L., McDonald C., Kong P., Baugh J., et al. Role for macrophage migration inhibitory factor in asthma. Proc Natl Acad Sci U S A 102 (2005) 14410-14415
46. Lolis E. Glucocorticoid counter regulation: macrophage migration inhibitory factor as a target for drug discovery. Curr Opin Pharmacol 1 (2001) 662-668
47. Morand E.F. New therapeutic target in inflammatory disease: macrophage migration inhibitory factor. Intern Med J 35 (2005) 419-426
48. Bozza F.A., Gomes R., Japiassu A.M., Soares M., Castro-Faria-Neto H., and Bozza P.T. Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 22 (2004) 309-313
49. Ohkawara T., Nishihira J., Takeda H., Hige S., Kato M., Sugiyama T., et al. Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice. Gastroenterology 123 (2002) 256-270
50. Sakai Y., Masamune A., Satoh A., Nishihira J., Yamagiwa T., and Shimosegawa T. Macrophage migration inhibitory factor is a critical mediator of severe acute pancreatitis. Gastroenterology 124 (2003) 725-736
51. Leech M., Metz C., Hall P., Hutchinson P., Gianis K., Smith M., et al. Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum 42 (1999) 1601-1608
52. Yabunaka N., Nishihira J., Mizue Y., Tsuji M., Kumagai M., Ohtsuka Y., et al. Elevated serum content of macrophage migration inhibitory factor in patients with type 2 diabetes. Diabetes Care 23 (2000) 256-258
53. Nicoletti F., Creange A., Orlikowski D., Bolgert F., Mangano K., Metz C., et al. Macrophage migration inhibitory factor (MIF) seems crucially involved in Guillain-Barre syndrome and experimental allergic neuritis. J Neuroimmunol 168 (2005) 168-174
54. Niino M., Ogata A., Kikuchi S., Tashiro K., and Nishihira J. Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-Behcet's disease. J Neurol Sci 179 (2000) 127-131
55. Burger-Kentischer A., Goebel H., Seiler R., Fraedrich G., Schaefer H.E., Dimmeler S., et al. Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation 105 (2002) 1561-1566
56. Kats R., Metz C.N., and Akoum A. Macrophage migration inhibitory factor is markedly expressed in active and early-stage endometriotic lesions. Clin Endocrinol Metab 87 (2002) 883-889
57. Murakami H., Akbar S.M., Matsui H., and Onji M. Macrophage migration inhibitory factor in the sera and at the colonic mucosa in patients with ulcerative colitis: clinical implications and pathogenic significance. Eur J Clin Invest 31 (2001) 337-343
58. Lan H.Y., Yang N., Nikolic-Paterson D.J., Yu X.Q., Mu W., Isbel N.M., et al. Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney Int 57 (2000) 499-509
59. Steinhoff M., Meinhardt A., Steinhoff A., Gemsa D., Bucala R., and Bacher M. Evidence for a role of macrophage migration inhibitory factor in psoriatic skin disease. Br J Dermatol 141 (1999) 1061-1066
60. Hanifi-Moghaddam P., Schloot N.C., Kappler S., Seisler J., and Kolb H. An association of autoantibody status and serum cytokine levels in type 1 diabetes. Diabetes 52 (2003) 1137-1142
61. Baugh J.A., Chitnis S., Donnely S.C., Monteiro J., Lin X., Plant B.J., et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun 3 (2002) 170-176
62. Donn R., Alourfi Z., De Benedetti F., Meazza C., Zeggini E., Lunt M., et al. Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum 46 (2002) 2402-2409
63. Amoli M.M., Donn R.P., Thomson W., Hajeer A.H., Garcia-Porrua C., Lueiro M., et al. Macrophage migration inhibitory factor gene polymorphism is associated with sarcoidosis in biopsy proven erythema nodosum. J Rheumatol 29 (2002) 1671-1673
64. Mizue Y., Ghani S., Leng L., McDonald C., Kong P., Baugh J., et al. Role for macrophage migration inhibitory factor in asthma. Proc Natl Acad Sci U S A 102 (2005) 14410-14415
65. Calandra T., Echtenacher B., Roy D.L., Pugin J., Metz C.N., Hultner L., et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 6 (2000) 164-170
66. Calandra T., Spiegel L.A., Metz C.N., and Bucala R. Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria. Proc Natl Acad Sci U S A 95 (1998) 11383-11388
67. Burger-Kentischer A., Gobel H., Kleemann R., Zernecke A., Bucala R., Leng L., et al. Reduction of the aortic inflammatory response in spontaneous atherosclerosis by blockade of macrophage migration inhibitory factor (MIF). J Atheroscler Res 184 (2006) 28-38
68. Lan H.Y., Bacher M., Yang N., Mu W., Nikolic-Paterson D.J., Metz C., et al. The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med 185 (1997) 1455-1465
69. Santos L., Hall P., Metz C., Bucala R., and Morand E.F. Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: interaction with glucocorticoids. Clin Exp Immunol 123 (2001) 309-314
70. Cvetkovic I., Al-Abed Y., Miljkovic D., Maksimovic-Ivanic D., Roth J., Bacher M., et al. Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology 146 (2005) 2942-2951
71. Casadevall A. Passive Antibody Therapies: Progress and Continuing Challenges. Clin Immunol 93 (1999) 5-15
72. Rosengren E., Aman P., Thelin S., Hansson C., Ahlfors S., Bjork P., et al. The macrophage migration inhibitory factor MIF is a phenylpyruvate tautomerase. FEBS Lett 417 (1997) 85-88
73. Kleemann R., Kapurniotu A., Frank R.W., Gessner A., Mischke R., Flieger O., et al. Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. J Mol Biol 280 (1998) 85-102
74. Swope M., Sun H.W., Blake P.R., and Lolis E. Direct link between cytokine activity and a catalytic site for macrophage migration inhibitory factor. EMBO J 17 (1998) 3534-3541
75. Lubetsky J.B., Dios A., Han J., Aljabari B., Ruzsicska B., Mitchell R., et al. The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J Biol Chem 277 (2002) 24976-24982
76. Dios A., Mitchell R.A., Aljabari B., Lubetsky J., O'Connor K., Liao H., et al. Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activity. J Med Chem 45 (2002) 2410-2416
77. Senter P.D., Al-Abed Y., Metz C.N., Benigni F., Mitchell R.A., Chesney J., et al. Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc Natl Acad Sci U S A 99 (2002) 144-149
78. Al-Abed Y., Dabideen D., Aljabari B., Valster A., Messmer D., Ochani M., et al. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem 280 (2005) 36541-36544
79. Morand E., Tapley P., Hall P., di Nezza L., Gilbert T., Yang Y., et al. Efficacy of a novel, orally active MIF antagonist in a model of rheumatoid arthritis. Inflamm Res 54 Suppl 2 (2005) 1036
80. -/- mice and an orally active MIF inhibitor attenuates atherosclerosis development. Inflamm Res 54 Suppl 2 (2005) 7115
81. Molnar V., and Garai J. Plant-derived anti-inflammatory compounds affect MIF tautomerase activity. Int Immunopharmacol 5 (2005) 849-856
82. Chen M.-F., Keng P.C., Lin P.-Y., Yang C.-T., Liao S., and Chen W.-C. Caffeic acid phenethyl ester decreases acute pneumonitis after irradiation in vitro and in vivo. BMC Cancer 5 (2005) 158-167
83. Park E.H., and Kahng J.H. Suppressive effects of propolis in rat adjuvant arthritis. Arch Pharm Res 22 (1999) 554-558
84. Backhouse N., Delporte C., Givernau M., Cassels G.K., Valenzuela A., and Speisky H. Anti-inflammatory and antipyretic effects of boldine. Agents Actions 42 (1994) 114-117
85. Thabrew M.I., Dharmasiri M.G., and Senaratne L.J. Anti-inflammatory and analgesic activity in the polyherbal formulation Maharasnadhi Quathar. J Ethnopharmacol 85 (2003) 261-267
86. Williams C.A., Hoult J.R.S., Harborne J.B., Greenham J., and Eagles J. A biologically active lipophilic flavonol from Tanacetum parthenium. Phytochemistry 38 (1995) 267-270
87. Koebernick H., Grode L., David J.R., Rohde W., Rolph M.S., Mittrücker H.-W., et al. Macrophage migration inhibitory factor (MIF) plays a pivotal role in immunity against Salmonella typhimurium. Proc Natl Acad Sci U S A 99 (2002) 13681-13686
88. Juttner S., Bernhagen J., Metz C.N., Rollinghoff M., Bucala R., and Gessner A. Migration inhibitory factor induces killing of Leishmania major by macrophages: dependence on reactive nitrogen intermediates and endogenous TNF-alpha. J Immunol 161 (1998) 2383-2390